Case of symptomatic mobile atheromatous plaque (MAP) at origin of internal carotid artery and management discussion: A case report

Mohamed Qadura¹, Faysal Naji¹, Rawand Abdin¹, Demetrios Sahlas², Khatija Pinky Ali¹*, Dawn Whyte³ and Vikram Iyer¹

¹Division of Vascular Surgery, McMaster University, Hamilton, Ontario, Canada
²Division of Neurology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
³Department of Diagnostic Imaging, Hamilton General Hospital, Hamilton, Ontario

Abstract

Background: Currently there is lack of consensus amongst physicians regarding the management of a mobile floating atheromatous plaque (MFAP). Our case report contributes to the on-going body of literature in an attempt to establish precedent on current management of MFAP.

Case report: 70-year-old man experienced a transient ischemic attack (TIA) with weakness in his right arm. Carotid duplex scan showed a mobile plaque in the left proximal internal carotid artery (ICA) with ICA/CCA ratio of 0.55 (<50% stenosis). The patient remained asymptomatic during his 10-day admission and was conservatively managed; with no complications post one-year follow up.

Conclusion: Mobile carotid lesions are a rare pathology with its management being supported by a limited but growing body of literature. We further demonstrate the efficacy of medical therapy in treating an atheromatous carotid plaque that has <50% stenosis. Our review further demonstrates medical therapy as being current preferred treatment modality by the majority of clinicians, and sheds light on the need for further investigation and characterizing and categorizing these mobile carotid lesions.

Introduction

A mobile atheromatous floating carotid plaque is an infrequent pathology, which occurs due to unknown mechanisms, and is often responsible for drastic outcomes [1]. Diagnostic imaging demonstrating mobile atheromatous plaque (MAP) at the carotid bifurcation or at the origin of the internal carotid artery (ICA) is a rare finding [2]. Currently, there is insufficient research and evidence regarding the management of this pathology. The current management of patients with mobile atheromatous floating plaques remains undetermined. Some authors proposed medical management using anti-platelet and/or anticoagulation therapy, whereas others favour surgical management.

Case report

A 70-year-old man presented to the emergency department with chief complaints of right arm weakness. His past medical history was significant for hypertension and hypercholesterolemia. A carotid duplex ultrasound showed an inhomogeneous soft appearing mobile plaque at the proximal left internal carotid artery (ICA) Figure 1, with peak systolic velocity of 49 cm/sec and an internal carotid artery/common carotid artery (ICA/CCA) ratio of 0.55 (<50% stenosis as per Carotid Consensus Criteria). Patients’ blood pressure maintained controlled with atenolol. He was started on pravastatin 20 mg daily and therapeutically anti-coagulated with a heparin infusion. Over the next 48 hours, he remained asymptomatic with a normal neurological examination. Heparin was then discontinued, and dual anti-platelet therapy was started (aspirin (ASA) 81 mg daily and clopidogrel 75 mg daily). Twenty-four hours later, a carotid CT angiogram (CTA) was conducted which showed no signs of intraluminal filling defects in the left CCA or ICA. A repeat U/S was done 72 hours later and showed an unchanged calcified inhomogeneous atheromatous plaque within the left carotid bulb extending into the origin of the ICA; however, the mobile plaque in the proximal ICA was no longer present. MRI of the brain nine days after admission to hospital showed small focal areas of acute infarction involving the left parietal lobe presumably secondary to thromboembolism from the left ICA. The patient remained asymptomatic during his length of stay of 10 days and was discharged home on ASA 81 mg daily, Clopidogrel 75 mg daily, Atenolol 50 mg BID and Pravastatin 20 mg daily.

One year later, the patient remained free of any symptoms of TIA or neurological dysfunctions. A repeat US showed a residual calcified plaque with no evidence of stenosis or mobility (Figure 2).

Discussion

The incidence of an MAFP is one in every 2000 patient, as a recent study showed [3-5]. Despite the epidemiology, current management of this condition is limited with no clinical trials conducted [1]. Bhatti et
Kim, showed two cases, which were also managed by anti-coagulation with no adverse effects post one-year, follow up [6].

The use of anti-coagulation allows the demolishment of floating plaques through plasmin, which will dissolve the clot by degrading fibrin [3]. Furthermore, it prevents the formation of future clots by inhibiting thrombin. Both physiological functions of anti-coagulation allow it to be a safe and logical action in patients with MFAP. Conducting an emergent endartectomy may be beneficial, but carries a high risk of neurological complications [7]. These complications can occur due to an emboli from the plaque, or by possible ischemic damage due to clamping of the carotid [4]. In the case of this patient, surgical intervention would in turn be considered in the case of worsening severity of the lesion, or if the patient had worsening symptomatology with inability to tolerate medical management.

**Conclusion**

In conclusion, the current body of literature on management of mobile carotid plaques has no consensus. Both medical and surgical methods are deemed appropriate. There are various cases, which argue for either side, with neither course of management showing superiority. Considering this, anti-coagulation alone was enough to prevent another stroke in our patient without the need of a surgical procedure.

**References**


**Copyright:** ©2017 Qadura M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.